POINT RICHMOND, Calif., Feb. 21, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Wednesday, February 27, 2013, at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2012 financial results. The conference call will follow the release of the Transcept fourth quarter and full year 2012 financial results after the close of market that day.
Conference Call Information
Date: Wednesday, February 27, 2013
Time: 4:30 p.m. ET
Dial-in (U.S.): 877-638-4558
Dial-in (International): 914-495-8537
A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call through March 31, 2013.
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.MyIntermezzo.com.
Transcept Pharmaceuticals, Inc.
Sr. Director, Corporate Communications
SOURCE Transcept Pharmaceuticals, Inc.